{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:59:45Z","timestamp":1794380385730,"version":"4.9.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008064","name":"Georgetown University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008064","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40268-019-0266-z","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T09:00:36Z","timestamp":1553677236000},"page":"149-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Multikinase Abl\/DDR\/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration"],"prefix":"10.1007","volume":"19","author":[{"given":"Alan J.","family":"Fowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaeline","family":"Hebron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Missner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahjat T.","family":"Kurd-Misto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel E.-H.","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"issue":"3","key":"266_CR1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12031-011-9588-1","volume":"45","author":"SD Schlatterer","year":"2011","unstructured":"Schlatterer SD, Acker CM, Davies P. c-Abl in neurodegenerative disease. J Mol Neurosci. 2011;45(3):445\u201352.","journal-title":"J Mol Neurosci."},{"key":"266_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2017.07.009","volume":"311","author":"M Hebron","year":"2017","unstructured":"Hebron M, Peyton M, Liu X, Gao X, Wang R, Lonskaya I, et al. Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models. J Neuroimmunol. 2017;311:1\u20139.","journal-title":"J Neuroimmunol."},{"issue":"8","key":"266_CR3","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/emmm.201302771","volume":"5","author":"I Lonskaya","year":"2013","unstructured":"Lonskaya I, Hebron ML, Desforges NM, Franjie A, Moussa CE. Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance. EMBO Mol Med. 2013;5(8):1247\u201362.","journal-title":"EMBO Mol Med."},{"issue":"8","key":"266_CR4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4161\/auto.25368","volume":"9","author":"ML Hebron","year":"2013","unstructured":"Hebron ML, Lonskaya I, Moussa CE. Tyrosine kinase inhibition facilitates autophagic SNCA\/alpha-synuclein clearance. Autophagy. 2013;9(8):1249\u201350.","journal-title":"Autophagy."},{"issue":"16","key":"266_CR5","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","volume":"22","author":"ML Hebron","year":"2013","unstructured":"Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson\u2019s disease models. Hum Mol Genet. 2013;22(16):3315\u201328.","journal-title":"Hum Mol Genet."},{"issue":"2","key":"266_CR6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3233\/JAD-2009-1062","volume":"17","author":"Z Jing","year":"2009","unstructured":"Jing Z, Caltagarone J, Bowser R. Altered subcellular distribution of c-Abl in Alzheimer\u2019s disease. J Alzheimers Dis. 2009;17(2):409\u201322.","journal-title":"J Alzheimers Dis."},{"issue":"38","key":"266_CR7","doi-asserted-by":"crossref","first-page":"16691","DOI":"10.1073\/pnas.1006083107","volume":"107","author":"HS Ko","year":"2010","unstructured":"Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, et al. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin\u2019s ubiquitination and protective function. Proc Natl Acad Sci USA. 2010;107(38):16691\u20136.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1","key":"266_CR8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1523\/JNEUROSCI.1833-10.2011","volume":"31","author":"SZ Imam","year":"2011","unstructured":"Imam SZ, Zhou Q, Yamamoto A, Valente AJ, Ali SF, Bains M, et al. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson\u2019s disease. J Neurosci. 2011;31(1):157\u201363.","journal-title":"J Neurosci."},{"issue":"1","key":"266_CR9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JAD-2011-102025","volume":"25","author":"SD Schlatterer","year":"2011","unstructured":"Schlatterer SD, Tremblay MA, Acker CM, Davies P. Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. J Alzheimers Dis. 2011;25(1):119\u201333.","journal-title":"J Alzheimers Dis."},{"issue":"8","key":"266_CR10","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1172\/JCI85456","volume":"126","author":"S Brahmachari","year":"2016","unstructured":"Brahmachari S, Ge P, Lee SH, Kim D, Karuppagounder SS, Kumar M, et al. Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-induced neurodegeneration. J Clin Investig. 2016;126(8):2970\u201388.","journal-title":"J Clin Investig."},{"issue":"2","key":"266_CR11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3233\/JAD-2010-1271","volume":"19","author":"MA Tremblay","year":"2010","unstructured":"Tremblay MA, Acker CM, Davies P. Tau phosphorylated at tyrosine 394 is found in Alzheimer\u2019s disease tangles and can be a product of the Abl-related kinase. Arg J Alzheimers Dis. 2010;19(2):721\u201333.","journal-title":"Arg J Alzheimers Dis."},{"issue":"13","key":"266_CR12","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","volume":"27","author":"S Lee","year":"2018","unstructured":"Lee S, Kim S, Park YJ, Yun SP, Kwon SH, Kim D, et al. The c-Abl inhibitor, radotinib HCl, is neuroprotective in a preclinical Parkinson\u2019s disease mouse model. Hum Mol Genet. 2018;27(13):2344\u201356.","journal-title":"Hum Mol Genet."},{"issue":"4","key":"266_CR13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0092-8674(93)90497-E","volume":"75","author":"PJ Welch","year":"1993","unstructured":"Welch PJ, Wang JY. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell. 1993;75(4):779\u201390.","journal-title":"Cell."},{"issue":"3","key":"266_CR14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1083\/jcb.124.3.325","volume":"124","author":"RA Etten Van","year":"1994","unstructured":"Van Etten RA, Jackson PK, Baltimore D, Sanders MC, Matsudaira PT, Janmey PA. The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J Cell Biol. 1994;124(3):325\u201340.","journal-title":"J Cell Biol."},{"issue":"49","key":"266_CR15","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1038\/sj.onc.1203878","volume":"19","author":"JY Wang","year":"2000","unstructured":"Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene. 2000;19(49):5643\u201350.","journal-title":"Oncogene."},{"issue":"8","key":"266_CR16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.cellsig.2006.02.012","volume":"18","author":"WF Vogel","year":"2006","unstructured":"Vogel WF, Abdulhussein R, Ford CE. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal. 2006;18(8):1108\u201316.","journal-title":"Cell Signal."},{"key":"266_CR17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainres.2010.03.099","volume":"1336","author":"B Roig","year":"2010","unstructured":"Roig B, Franco-Pons N, Martorell L, Tomas J, Vogel WF, Vilella E. Expression of the tyrosine kinase discoidin domain receptor 1 (DDR1) in human central nervous system myelin. Brain Res. 2010;1336:22\u20139.","journal-title":"Brain Res."},{"issue":"5","key":"266_CR18","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/jnr.21552","volume":"86","author":"MC Seo","year":"2008","unstructured":"Seo MC, Kim S, Kim SH, Zheng LT, Park EK, Lee WH, et al. Discoidin domain receptor 1 mediates collagen-induced inflammatory activation of microglia in culture. J Neurosci Res. 2008;86(5):1087\u201395.","journal-title":"J Neurosci Res."},{"issue":"14","key":"266_CR19","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1096\/fj.01-0359fje","volume":"15","author":"H Kamohara","year":"2001","unstructured":"Kamohara H, Yamashiro S, Galligan C, Yoshimura T. Discoidin domain receptor 1 isoform-a (DDR1alpha) promotes migration of leukocytes in three-dimensional collagen lattices. FASEB J. 2001;15(14):2724\u20136.","journal-title":"FASEB J."},{"issue":"1","key":"266_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-018-0497-5","volume":"32","author":"AJ Fowler","year":"2018","unstructured":"Fowler AJ, Moussa CE. Activating autophagy as a therapeutic strategy for Parkinson\u2019s disease. CNS Drugs. 2018;32(1):1\u201311.","journal-title":"CNS Drugs."},{"issue":"27","key":"266_CR21","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1523\/JNEUROSCI.0800-08.2008","volume":"28","author":"B Boland","year":"2008","unstructured":"Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer\u2019s disease. J Neurosci. 2008;28(27):6926\u201337.","journal-title":"J Neurosci."},{"issue":"27","key":"266_CR22","doi-asserted-by":"crossref","first-page":"25009","DOI":"10.1074\/jbc.M300227200","volume":"278","author":"JL Webb","year":"2003","unstructured":"Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278(27):25009\u201313.","journal-title":"J Biol Chem."},{"issue":"24","key":"266_CR23","doi-asserted-by":"crossref","first-page":"9549","DOI":"10.1523\/JNEUROSCI.21-24-09549.2001","volume":"21","author":"L Stefanis","year":"2001","unstructured":"Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 2001;21(24):9549\u201360.","journal-title":"J Neurosci."},{"issue":"9","key":"266_CR24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","volume":"6","author":"DM Sabatini","year":"2006","unstructured":"Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6(9):729\u201334.","journal-title":"Nat Rev Cancer."},{"issue":"9","key":"266_CR25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/hmg\/11.9.1107","volume":"11","author":"B Ravikumar","year":"2002","unstructured":"Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet. 2002;11(9):1107\u201317.","journal-title":"Hum Mol Genet."},{"issue":"2","key":"266_CR26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnen\/64.2.113","volume":"64","author":"RA Nixon","year":"2005","unstructured":"Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005;64(2):113\u201322.","journal-title":"J Neuropathol Exp Neurol."},{"issue":"19","key":"266_CR27","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1523\/JNEUROSCI.20-19-07268.2000","volume":"20","author":"KB Kegel","year":"2000","unstructured":"Kegel KB, Kim M, Sapp E, McIntyre C, Castano JG, Aronin N, et al. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci. 2000;20(19):7268\u201378.","journal-title":"J Neurosci."},{"issue":"10","key":"266_CR28","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1111\/j.1460-9568.2007.05914.x","volume":"26","author":"Y Yang","year":"2007","unstructured":"Yang Y, Fukui K, Koike T, Zheng X. Induction of autophagy in neurite degeneration of mouse superior cervical ganglion neurons. Eur J Neurosci. 2007;26(10):2979\u201388.","journal-title":"Eur J Neurosci."},{"key":"266_CR29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neuroscience.2012.12.018","volume":"232","author":"I Lonskaya","year":"2013","unstructured":"Lonskaya I, Hebron ML, Algarzae NK, Desforges N, Moussa CE. Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson\u2019s disease. Neuroscience. 2013;232:90\u2013105.","journal-title":"Neuroscience."},{"issue":"1","key":"266_CR30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-2012-121141","volume":"33","author":"I Lonskaya","year":"2013","unstructured":"Lonskaya I, Shekoyan AR, Hebron ML, Desforges N, Algarzae NK, Moussa CE. Diminished parkin solubility and co-localization with intraneuronal amyloid-beta are associated with autophagic defects in Alzheimer\u2019s disease. J Alzheimers Dis. 2013;33(1):231\u201347.","journal-title":"J Alzheimers Dis."},{"issue":"11","key":"266_CR31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","journal-title":"N Engl J Med."},{"issue":"23","key":"266_CR32","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med."},{"issue":"6","key":"266_CR33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4155\/fmc.12.29","volume":"4","author":"F Musumeci","year":"2012","unstructured":"Musumeci F, Schenone S, Brullo C, Botta M. An update on dual Src\/Abl inhibitors. Fut Med Chem. 2012;4(6):799\u2013822.","journal-title":"Fut Med Chem."},{"issue":"10","key":"266_CR34","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540\u20136.","journal-title":"Blood."},{"issue":"5","key":"266_CR35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000430888","volume":"15","author":"CE Moussa","year":"2015","unstructured":"Moussa CE. Parkin is dispensable for mitochondrial function, but its ubiquitin ligase activity is critical for macroautophagy and neurotransmitters: therapeutic potential beyond Parkinson\u2019s disease. Neurodegener Dis. 2015;15(5):259\u201370.","journal-title":"Neurodegener Dis."},{"key":"266_CR36","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuroscience.2015.07.070","volume":"304","author":"I Lonskaya","year":"2015","unstructured":"Lonskaya I, Hebron ML, Selby ST, Turner RS, Moussa CE. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer\u2019s disease models. Neuroscience. 2015;304:316\u201327.","journal-title":"Neuroscience."},{"issue":"4","key":"266_CR37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00109-013-1112-3","volume":"92","author":"I Lonskaya","year":"2014","unstructured":"Lonskaya I, Hebron ML, Desforges NM, Schachter JB, Moussa CE. Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med (Berl). 2014;92(4):373\u201386.","journal-title":"J Mol Med (Berl)."},{"issue":"12","key":"266_CR38","doi-asserted-by":"crossref","first-page":"e83914","DOI":"10.1371\/journal.pone.0083914","volume":"8","author":"I Lonskaya","year":"2013","unstructured":"Lonskaya I, Desforges NM, Hebron ML, Moussa CE. Ubiquitination increases parkin activity to promote autophagic alpha-synuclein clearance. PLoS One. 2013;8(12):e83914.","journal-title":"PLoS One."},{"key":"266_CR39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4172\/2155-9899.1000259","volume":"5","author":"ML Hebron","year":"2014","unstructured":"Hebron ML, Lonskaya I, Olopade P, Selby ST, Pagan F, Moussa CE. Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in alpha-synucleinopathy. J Clin Cell Immunol. 2014;5:259.","journal-title":"J Clin Cell Immunol."},{"issue":"3","key":"266_CR40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","volume":"6","author":"F Pagan","year":"2016","unstructured":"Pagan F, Hebron M, Valadez EH, Torres-Yaghi Y, Huang X, Mills RR, et al. Nilotinib effects in Parkinson\u2019s disease and dementia with Lewy bodies. J Parkinsons Dis. 2016;6(3):503\u201317.","journal-title":"J Parkinsons Dis."},{"issue":"9","key":"266_CR41","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25(9):1035\u201344.","journal-title":"Nat Biotechnol."},{"issue":"12","key":"266_CR42","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110(12):4055\u201363.","journal-title":"Blood."},{"issue":"6","key":"266_CR43","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1053\/j.gastro.2006.09.017","volume":"131","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW, et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology. 2006;131(6):1734\u201342.","journal-title":"Gastroenterology."},{"issue":"1","key":"266_CR44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11(1):84.","journal-title":"J Hematol Oncol."},{"issue":"3","key":"266_CR45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nn.4489","volume":"20","author":"K Kisler","year":"2017","unstructured":"Kisler K, Nelson AR, Rege SV, Ramanathan A, Wang Y, Ahuja A, et al. Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain. Nat Neurosci. 2017;20(3):406\u201316.","journal-title":"Nat Neurosci."},{"issue":"3","key":"266_CR46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuron.2010.09.043","volume":"68","author":"RD Bell","year":"2010","unstructured":"Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68(3):409\u201327.","journal-title":"Neuron."},{"issue":"5","key":"266_CR47","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nn.3357","volume":"16","author":"SH Kang","year":"2013","unstructured":"Kang SH, Li Y, Fukaya M, Lorenzini I, Cleveland DW, Ostrow LW, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16(5):571\u20139.","journal-title":"Nat Neurosci."},{"key":"266_CR48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2202-13-12","volume":"13","author":"A Massella","year":"2012","unstructured":"Massella A, D\u2019Intino G, Fernandez M, Sivilia S, Lorenzini L, Giatti S, et al. Gender effect on neurodegeneration and myelin markers in an animal model for multiple sclerosis. BMC Neurosci. 2012;13:12.","journal-title":"BMC Neurosci."},{"key":"266_CR49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mam.2017.11.007","volume":"62","author":"N Papadopoulos","year":"2018","unstructured":"Papadopoulos N, Lennartsson J. The PDGF\/PDGFR pathway as a drug target. Mol Asp Med. 2018;62:75\u201388.","journal-title":"Mol Asp Med."},{"key":"266_CR50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2018.06.005","volume":"391","author":"ML Hebron","year":"2018","unstructured":"Hebron ML, Javidnia M, Moussa CE. Tau clearance improves astrocytic function and brain glutamate-glutamine cycle. J Neurol Sci. 2018;391:90\u20139.","journal-title":"J Neurol Sci."},{"issue":"3","key":"266_CR51","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"LL Remsing Rix","year":"2009","unstructured":"Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23(3):477\u201385.","journal-title":"Leukemia."},{"issue":"23","key":"266_CR52","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1021\/jm0102250","volume":"44","author":"DH Boschelli","year":"2001","unstructured":"Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem. 2001;44(23):3965\u201377.","journal-title":"J Med Chem."},{"issue":"5","key":"266_CR53","doi-asserted-by":"crossref","first-page":"e65129","DOI":"10.1371\/journal.pone.0065129","volume":"8","author":"SZ Imam","year":"2013","unstructured":"Imam SZ, Trickler W, Kimura S, Binienda ZK, Paule MG, Slikker W Jr, et al. Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson\u2019s disease model. PLoS One. 2013;8(5):e65129.","journal-title":"PLoS One."},{"issue":"13","key":"266_CR54","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","volume":"27","author":"S Lee","year":"2018","unstructured":"Lee S, Kim S, Park YJ, Yun SP, Kwon S-H, Kim D, et al. The c-Abl inhibitor, radotinib HCl is neuroprotective in a preclinical Parkinson\u2019s disease mouse model. Hum Mol Genet. 2018;27(13):2344\u201356.","journal-title":"Hum Mol Genet."},{"issue":"3","key":"266_CR55","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/jpet.111.187328","volume":"340","author":"X Sun","year":"2012","unstructured":"Sun X, Phan TN, Jung SH, Kim SY, Cho JU, Lee H, et al. LCB 03-0110, a novel pan-discoidin domain receptor\/c-Src family tyrosine kinase inhibitor, suppresses scar formation by inhibiting fibroblast and macrophage activation. J Pharmacol Exp Ther. 2012;340(3):510\u20139.","journal-title":"J Pharmacol Exp Ther."},{"issue":"4","key":"266_CR56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","volume":"34","author":"BI Giasson","year":"2002","unstructured":"Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34(4):521\u201333.","journal-title":"Neuron."},{"issue":"18","key":"266_CR57","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1093\/hmg\/ddu211","volume":"23","author":"C Wenqiang","year":"2014","unstructured":"Wenqiang C, Lonskaya I, Hebron ML, Ibrahim Z, Olszewski RT, Neale JH, et al. Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice. Hum Mol Genet. 2014;23(18):4960\u20139.","journal-title":"Hum Mol Genet."},{"issue":"2","key":"266_CR58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/JAD-170429","volume":"60","author":"M Javidnia","year":"2017","unstructured":"Javidnia M, Hebron ML, Xin Y, Kinney NG, Moussa CE. Pazopanib reduces phosphorylated tau levels and alters astrocytes in a mouse model of tauopathy. J Alzheimers Dis. 2017;60(2):461\u201381.","journal-title":"J Alzheimers Dis."},{"issue":"11","key":"266_CR59","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/cdd.2008.107","volume":"15","author":"Y Kamitsuji","year":"2008","unstructured":"Kamitsuji Y, Kuroda J, Kimura S, Toyokuni S, Watanabe K, Ashihara E, et al. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ. 2008;15(11):1712\u201322.","journal-title":"Cell Death Differ."},{"issue":"12","key":"266_CR60","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, et al. NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005;106(12):3948\u201354.","journal-title":"Blood."},{"issue":"8","key":"266_CR61","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1349-7006.2007.00516.x","volume":"98","author":"J Pan","year":"2007","unstructured":"Pan J, Quintas-Cardama A, Manshouri T, Cortes J, Kantarjian H, Verstovsek S. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Sci. 2007;98(8):1223\u20135.","journal-title":"Cancer Sci."},{"issue":"8","key":"266_CR62","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648\u201371.","journal-title":"Leukemia."},{"issue":"2","key":"266_CR63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.drudis.2014.09.025","volume":"20","author":"S Kothiwale","year":"2015","unstructured":"Kothiwale S, Borza CM, Lowe EW Jr, Pozzi A, Meiler J. Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery. Drug Discov Today. 2015;20(2):255\u201361.","journal-title":"Drug Discov Today."},{"issue":"17","key":"266_CR64","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00018-014-1616-1","volume":"71","author":"LK Iwai","year":"2014","unstructured":"Iwai LK, Luczynski MT, Huang PH. Discoidin domain receptors: a proteomic portrait. Cell Mol Life Sci. 2014;71(17):3269\u201379.","journal-title":"Cell Mol Life Sci."},{"issue":"10","key":"266_CR65","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1021\/cb400430t","volume":"8","author":"HG Kim","year":"2013","unstructured":"Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol. 2013;8(10):2145\u201350.","journal-title":"ACS Chem Biol."},{"key":"266_CR66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13024-016-0076-5","volume":"11","author":"E Sempou","year":"2016","unstructured":"Sempou E, Biasini E, Pinzon-Olejua A, Harris DA, Malaga-Trillo E. Activation of zebrafish Src family kinases by the prion protein is an amyloid-beta-sensitive signal that prevents the endocytosis and degradation of E-cadherin\/beta-catenin complexes in vivo. Mol Neurodegener. 2016;11:18.","journal-title":"Mol Neurodegener."},{"issue":"7","key":"266_CR67","doi-asserted-by":"crossref","first-page":"e0132604","DOI":"10.1371\/journal.pone.0132604","volume":"10","author":"GD Manocha","year":"2015","unstructured":"Manocha GD, Puig KL, Austin SA, Seyb K, Glicksman MA, Combs CK. Characterization of novel Src family kinase inhibitors to attenuate microgliosis. PLoS One. 2015;10(7):e0132604.","journal-title":"PLoS One."},{"issue":"1","key":"266_CR68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/leu.2009.228","volume":"24","author":"U Rix","year":"2010","unstructured":"Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, et al. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia. 2010;24(1):44\u201350.","journal-title":"Leukemia."},{"key":"266_CR69","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-2-14","volume":"2","author":"E Croisier","year":"2005","unstructured":"Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation. 2005;2:14.","journal-title":"J Neuroinflammation."},{"issue":"3","key":"266_CR70","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"H Akiyama","year":"2000","unstructured":"Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer\u2019s disease. Neurobiol Aging. 2000;21(3):383\u2013421.","journal-title":"Neurobiol Aging."},{"issue":"10","key":"266_CR71","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/CIRCRESAHA.107.170662","volume":"102","author":"C Franco","year":"2008","unstructured":"Franco C, Hou G, Ahmad PJ, Fu EY, Koh L, Vogel WF, et al. Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice. Circ Res. 2008;102(10):1202\u201311.","journal-title":"Circ Res."},{"issue":"4","key":"266_CR72","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1164\/rccm.200603-333OC","volume":"174","author":"C Avivi-Green","year":"2006","unstructured":"Avivi-Green C, Singal M, Vogel WF. Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2006;174(4):420\u20137.","journal-title":"Am J Respir Crit Care Med."},{"issue":"12","key":"266_CR73","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1681\/ASN.2006060677","volume":"17","author":"M Flamant","year":"2006","unstructured":"Flamant M, Placier S, Rodenas A, Curat CA, Vogel WF, Chatziantoniou C, et al. Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. J Am Soc Nephrol. 2006;17(12):3374\u201381.","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"266_CR74","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/CIRCRESAHA.109.207357","volume":"105","author":"C Franco","year":"2009","unstructured":"Franco C, Britto K, Wong E, Hou G, Zhu SN, Chen M, et al. Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis. Circ Res. 2009;105(11):1141\u20138.","journal-title":"Circ Res."},{"issue":"1","key":"266_CR75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2016.06.009","volume":"166","author":"H Gao","year":"2016","unstructured":"Gao H, Chakraborty G, Zhang Z, Akalay I, Gadiya M, Gao Y, et al. Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling. Cell. 2016;166(1):47\u201362.","journal-title":"Cell."},{"key":"266_CR76","first-page":"32","volume":"4","author":"SE Lakhan","year":"2013","unstructured":"Lakhan SE, Kirchgessner A, Tepper D, Leonard A. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol. 2013;4:32.","journal-title":"Front Neurol."},{"issue":"3","key":"266_CR77","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12031-011-9620-5","volume":"46","author":"Y Wu","year":"2012","unstructured":"Wu Y, Wang YP, Guo P, Ye XH, Wang J, Yuan SY, et al. A lipoxin A4 analog ameliorates blood-brain barrier dysfunction and reduces MMP-9 expression in a rat model of focal cerebral ischemia-reperfusion injury. J Mol Neurosci. 2012;46(3):483\u201391.","journal-title":"J Mol Neurosci."},{"key":"266_CR78","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neures.2015.01.004","volume":"96","author":"M Zhu","year":"2015","unstructured":"Zhu M, Xing D, Lu Z, Fan Y, Hou W, Dong H, et al. DDR1 may play a key role in destruction of the blood-brain barrier after cerebral ischemia-reperfusion. Neurosci Res. 2015;96:14\u20139.","journal-title":"Neurosci Res."},{"issue":"8","key":"266_CR79","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.cellsig.2010.03.001","volume":"22","author":"JM Bradshaw","year":"2010","unstructured":"Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal. 2010;22(8):1175\u201384.","journal-title":"Cell Signal."},{"issue":"3","key":"266_CR80","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445\u201353.","journal-title":"Biochim Biophys Acta."},{"key":"266_CR81","unstructured":"Selleckchem. Bafetinib (INNO-406) (NS-187). 2013. \n                    https:\/\/www.selleckchem.com\/products\/Bafetinib.html\n                    \n                  . Accessed 14 Mar 2019."},{"issue":"9","key":"266_CR82","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620717719851","volume":"8","author":"AE Eskazan","year":"2017","unstructured":"Eskazan AE, Keskin D. Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. Ther Adv Hematol. 2017;8(9):237\u201343.","journal-title":"Ther Adv Hematol."},{"issue":"7","key":"266_CR83","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2013.096776","volume":"99","author":"SH Kim","year":"2014","unstructured":"Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014;99(7):1191\u20136.","journal-title":"Haematologica."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-0266-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-019-0266-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-019-0266-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:33:27Z","timestamp":1585182807000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-019-0266-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["266"],"URL":"https:\/\/doi.org\/10.1007\/s40268-019-0266-z","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"27 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"These studies were supported by funding from Georgetown University to Charbel Moussa.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Charbel Moussa is listed as an inventor of an issued US and international patent to use tyrosine kinase inhibitors to treat neurodegenerative diseases. No other author has any conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All mouse studies were conducted in full compliance with the recommendations of the Georgetown University Animal Care and Use Committee under protocol 2016-1194.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All data generated or analyzed during this study are included in this article (and the Electronic Supplementary Material).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}